INTRODUCTION
============

Carpal tunnel syndrome (CTS) is an entrapment mononeuropathy that is commonly observed in clinical practice and is caused by the compression of the median nerve at the wrist ([@b1-cln_69p524]). When the median nerve is compressed in the tunnel, the patient develops the signs and symptoms of CTS. The most common symptoms of CTS include pain, paresthesia, numbness or tingling involving the fingers that are innervated by the median nerve and a weakness of thumb abduction. The symptoms are at their worst at night and often wake the patient ([@b2-cln_69p524]).

Both conservative and surgical treatments are used to relieve the pressure on the median nerve ([@b1-cln_69p524]). The choice between conservative and surgical treatment is determined by the severity of the symptoms and the patient\'s physical limitations ([@b3-cln_69p524]).

Conservative treatment of CTS would seem to be preferable as the initial treatment choice, particularly for mild to moderate cases ([@b1-cln_69p524]). However, the efficacy of conservative treatment options for CTS is controversial ([@b1-cln_69p524]). Ultrasound (US) is a widely used and accepted adjunct modality for the management of many musculoskeletal conditions ([@b4-cln_69p524]). US converts electrical energy into an acoustic waveform, which is then converted into heat as it passes through tissues of varying resistance ([@b5-cln_69p524]). Therapeutic US is reported to reduce edema, relieve pain and accelerate tissue repair ([@b6-cln_69p524]-[@b8-cln_69p524]). The exact mechanism of action of therapeutic US remains to be elucidated, although it is used to treat various musculoskeletal disorders. Analgesia that is induced by therapeutic US may be the result of increased capillary permeability and tissue metabolism, the enhancement of fibrous tissue extensibility and the elevation of the pain threshold by thermal mechanisms ([@b6-cln_69p524],[@b9-cln_69p524]). Therapeutic US can be applied as pulsed or continuous therapy.

Only a few studies have reported the benefits of therapeutic US in CTS patients and there are conflicting results on its efficacy in the treatment of CTS ([@b1-cln_69p524],[@b10-cln_69p524],[@b11-cln_69p524]). Recently, the effectiveness of pulsed and continuous US therapy was compared with a placebo and the authors reported satisfactory effects in patients with mild to moderate CTS ([@b10-cln_69p524],[@b12-cln_69p524],[@b13-cln_69p524]).

Splinting is the most popular method among the conservative treatments that are available for CTS ([@b13-cln_69p524]-[@b15-cln_69p524]). Immobilization of the wrist in a neutral position with a splint maximizes the carpal tunnel volume and minimizes the pressure on the median nerve ([@b1-cln_69p524]).

The aim of this study was to evaluate the effects of pulsed and continuous US treatments in combination with splint therapy on patients with mild and moderate idiopathic CTS compared to a placebo.

METHODS
=======

The study was carried out at the outpatient clinic of the Eskisehir Osmangazi University Faculty of Medicine, Department of Physical Medicine and Rehabilitation between October 2011 and January 2013. A total of 36 female patients with clinical and electrophysiological evidence of mild or moderate idiopathic CTS (without thenar atrophy or spontaneous activity as determined by the electrophysiological examination of the abductor pollicis brevis (APB) muscle) were included in the study. All of the patients had unilateral CTS and were right-handed.

Patients were excluded if they had secondary entrapment neuropathies, cervical radiculopathy or systemic diseases that are associated with increased CTS risk in addition to those who had undergone surgery for the syndrome, had been treated with US or had a history of steroid injections into the carpal tunnel and physical therapy within the last 3 months. Additionally, patients with either thenar atrophy or spontaneous activity (fibrillation potentials and positive sharp waves) as determined by an electrophysiological examination of the APB muscle were excluded from the study.

Study design
------------

This study was designed as a prospective, randomized, placebo-controlled, double-blind study. All of the patients were assessed by the same physiatrist before beginning treatment and at the end of the three weeks of treatment. Before initiation and after the three weeks, all of the patients were assessed by the same physiatrist. Neither the investigator nor the patients were informed of the treatment assignments. The study was conducted in full compliance with the amended Declaration of Helsinki after obtaining approval from the institutional review board of Eskisehir Osmangazi University (date/n°: 18-05-2012/127). Following baseline assessments, the patients who fulfilled the inclusion criteria and were included in the study were randomly assigned to one of three groups using a secure system of opaque closed envelopes that were numbered from 1 to 3.

Forty-six patients were randomly assigned to one of the three groups: group 1 (n = 15) received splinting and continuous US therapy; group 2 (n = 16) received splinting and pulsed US therapy and group 3 (n = 15) received splinting and a 'sham\' (placebo) US therapy.

Treatment protocol
------------------

Custom-made neutral volar splints were given to all of the patients that were included in the study. They were instructed to wear the splints at night and during the day for a total of three weeks.

Continuous, pulsed and sham US therapies were performed on all of the patients by the same physiotherapist. In group 1 (continuous US group), US treatments were administered to the carpal tunnel area at a frequency of 1 with an intensity of 1 W/cm^2^ and a transducer of 5 cm^2^ in size (Sonopuls 434; Enraf Nonius, Delft, The Netherlands), using aquasonic gel that did not contain any pharmacologically active substances. The apparatus was initially standardized and the output was controlled by a simple underwater radiation balance.

In group 2 (pulsed US group), the same US equipment was set at a frequency of 1 MHz with an intensity of 1 W/cm^2^ and a pulsed mode duty cycle of 1:4. The duration of the applied US and the posture of the patient being treated were the same as those that were described for the continuous US group. The patients in group 3 (placebo US group) received a 'sham\' US application wherein the US device that was described above appeared to be working but did not deliver any output. US treatment sessions were performed once a day, five days a week, for a total of three weeks.

Evaluations
-----------

All of the patients were evaluated immediately before and after the three-week treatment by a blinded investigator with respect to the parameters that are described below.

Electrophysiological evaluations
--------------------------------

Electrophysiological evaluations were performed at baseline and at the end of the treatment. Using standard techniques, all of the electrodiagnostic tests were performed by the same physician using a Medelec Sapphire 4 ME (Medelec, Old Woking, UK) electromyography apparatus. The hands of each patient were warmed prior to testing by seating them for 15 minutes in an examining room at a temperature of 22-24°C. To evaluate the median nerve, motor distal latency (DL), motor nerve conduction velocity (NCV), sensory DL and palm-wrist sensory NCV measurements were measured in all patients. Surface stimulation and recording electrodes were used for the sensory and NCV tests employing standard methodology ([@b16-cln_69p524]). The compound muscle action potentials of the abductor pollicis brevis muscle that were induced by supramaximal electrical stimulation on the median nerve at the wrist 8 cm from the recording electrode were recorded. DL and NCV studies were performed from the wrist to the APB muscle at a distance of 8 cm. For the sensory nerve conduction studies, the median sensory fibers were stimulated antidromically at the midpalm and wrist at distances of 7 cm and 14 cm from the recording ring electrode that was looped around the proximal interphalangeal joint of the third digit. The onset latencies of the negative potentials were taken into consideration. For sensory testing, the sweep-speed velocity was set at 10 msec, whereas for motor testing, it was set at 30 msec; the duration of the stimulus was 0.1 msec in both studies. The voltage was increased until the action potentials reached maximal amplitude. The main electrophysiological criteria for the diagnosis of CTS were the slowing of sensory nerve conduction velocity of the median nerve in the palm-wrist segment or an absence of sensory nerve action potential of the median nerve that was accompanied by prolonged terminal motor latency ([@b17-cln_69p524]). In our electrophysiology laboratory, if the median nerve DL was 3.9 msn or above, the median nerve sensory latency was 3 msn or above and the sensory nerve conduction velocity of the median nerve in the palm-wrist segment was 35.2 m/sn or below, the subjects were considered to have CTS.

Clinical assessment
-------------------

A blinded physician who was unaware of the treatment allocations performed the clinical assessments at baseline and at the end of the treatments. Symptom Severity scores (SSSs), Functional Status scores (FSSs) and a Visual Analog Scale (VAS) were used for the clinical follow-up and evaluation of the patients.

The severity of the pain was assessed using a VAS consisting of 10-cm horizontal lines with anchor points of 0 (no pain) and 10 (maximum pain). The Symptom Severity Scale has 11 items in relation to pain, including nocturnal symptoms, numbness, tingling and weakness ([@b18-cln_69p524]). The Functional Status Scale encompasses 8 items (difficulty in writing, buttoning clothes, opening jars, holding a book, gripping a telephone handle, performing household chores, carrying grocery bags, bathing and dressing). Each item in these scales has five ordinal response categories, ranging from 1 (no symptoms or no difficulty) to 5 (severe symptoms).

Statistical analyses
--------------------

Statistical analyses were performed using SPSS 18.0 for Windows. The normality of the distribution of the data was confirmed by the Kolmogorov-Smirnov test. The results were analyzed by a one-way ANOVA with post-hoc Tukey HSD tests and t-tests. The results were reported as the mean±SD. Power calculations were evaluated using a one-way ANOVA and the power of the study was 0.70 (70%). The significance level was set at *p*\<0.05.

RESULTS
=======

[Table 1](#t1-cln_69p524){ref-type="table"}) shows the demographic characteristics of the study groups. No significant differences were observed between the groups. There were significant improvements in all groups for all clinical parameters. There were no significant differences between the groups ([Table 2](#t2-cln_69p524){ref-type="table"}).

[Table 3](#t3-cln_69p524){ref-type="table"}) shows a comparison of the electrophysiological measurements that were obtained before and after the treatments. The sensory conduction velocity of the median nerve showed improvement in the second and third groups, the sensory DL of the median nerve (digit II to palm) improved only in the third group, and the sensory DL of the median nerve (palm to wrist) improved only in the second group. There were no significant differences between the groups.

DISCUSSION
==========

CTS is one of the most common hand disorders. The highest incidence is among middle-aged and elderly women ([@b19-cln_69p524]). Although several treatment modalities are routinely used, there is no consensus regarding the best way to manage CTS. The aim of this placebo-controlled study was to evaluate the effects of pulsed and continuous US treatments in combination with splinting therapy on various clinical and electrophysiological parameters in patients with CTS.

Splinting is the most popular method among the conservative treatment modalities that are available for CTS ([@b14-cln_69p524],[@b15-cln_69p524]). The efficacy of wrist splinting therapy has been variably demonstrated in several studies ([@b15-cln_69p524],[@b20-cln_69p524],[@b21-cln_69p524]). Premoselli et al. reported that splinting therapy improved symptoms and electrophysiological parameters in CTS patients ([@b21-cln_69p524]).

In our study, a night rest splint was used by all of the participants and clinical improvement was observed in all of the groups. Placebo US can lead to symptom relief by producing a local massage effect; however, this symptomatic improvement may be, in fact, related to the splinting therapy, as has been observed in recent studies investigating the beneficial effects of splinting therapy in CTS. Electrophysiological improvement was found in the continuous and pulsed US groups but not in the placebo group.

US is used extensively in musculoskeletal disorders. A few studies have found US therapy to be effective for CTS ([@b10-cln_69p524],[@b12-cln_69p524],[@b13-cln_69p524]). However, a consensus has yet to be reached regarding the optimal therapeutic US parameters (intensity, frequency of sound waves, duration, pulse, etc.) ([@b1-cln_69p524],[@b10-cln_69p524],[@b13-cln_69p524],[@b22-cln_69p524]).

Therapeutic US can be applied in a pulsed or continuous manner. Pulsed US has been recommended for acute pain and inflammation, whereas continuous US has been recommended for the treatment of restricted movement ([@b23-cln_69p524]). Pulsed US produces non-thermal effects and is used to aid in the reduction of inflammation, whereas continuous US generates thermal effects ([@b6-cln_69p524]).

The aim of this study was to compare the effects of pulsed and continuous US treatments on patients with CTS. In the placebo-controlled study that was conducted by Ebenbichler et al., the US method was similar to that which was used in our study with the exception of the therapy time (1 MHz, 1.0 W/cm^2^ in pulsed mode 1:4 for 15 min per session). This group revealed the clinical and electrophysiological improvement of CTS symptoms ([@b10-cln_69p524]). In another study comparing the efficiency of US and laser therapy, US (1 MHz, 1.0 W/cm^2^ in pulsed mode 1:4 for 15 min per session) was found to be more effective than laser therapy for CTS in terms of electrophysiological parameters ([@b22-cln_69p524]). US therapy in combination with splinting therapy was compared with ketoprofen phonophoresis in a placebo-controlled study and the electrophysiological and clinical parameters were reported to improve in both groups ([@b24-cln_69p524]). Electrophysiological and clinical improvements were observed in our study in the pulsed US group. These results are in agreement with those from other studies, although there are some methodological differences.

In the group that received continuous US therapy in combination with splinting therapy, the treatment was applied for 10 min per session to the carpal tunnel area at a frequency of 1 and an intensity of 1 W/cm^2^. The efficacy of continuous US in CTS has been previously evaluated in only a few studies ([@b12-cln_69p524],[@b25-cln_69p524],[@b26-cln_69p524]). A placebo-controlled study reported clinical and electrophysiological improvement using different doses of US therapy (1.5 W/cm^2^, 0.8 W/cm^2^, 0 W/cm^2^). In addition, the NCV decreased slightly and DL increased in the US group ([@b13-cln_69p524]). In a placebo-controlled study evaluating low-intensity (0.5 W/cm^2^) US, a significant improvement in clinical variables was observed after the treatment, although there were no differences in the electrophysiological variables ([@b12-cln_69p524]). In another placebo-controlled study, clinical improvement was observed with US therapy (1.5 W/cm^2^); however, no electrophysiological improvement was found ([@b25-cln_69p524]).

Because the US intensities that were used differ in all of these studies, it is difficult to compare results. Furthermore, there is no consensus in the literature regarding the effective dose for US therapy. Similarly to our study, Dincer et al. compared splinting therapy alone with continuous US therapy (at an intensity of 1.0 W/cm^2^) combined with splinting therapy in addition to laser therapy combined with splinting therapy and found clinical and electrophysiological improvement in the combined therapy groups ([@b26-cln_69p524]).

US is assumed to be an anti-inflammatory procedure that increases blood flow, local metabolism and tissue regeneration in target tissues in addition to reducing edema and pain and limiting nerve compression ([@b1-cln_69p524]).

Evidence of an anti-inflammatory effect of US treatment from experiments on the stimulation of nerve regeneration and on nerve conduction supports the idea that US treatment may facilitate recovery from nerve compression ([@b27-cln_69p524]-[@b30-cln_69p524]).

In our study, the patients that were treated with pulsed and continuous US showed electrophysiological improvement; however, these results were not superior to those that were observed with the placebo. We believe that this electrophysiological improvement is related to the mechanism of action of the US therapy. Further, the lack of intergroup differences in the electrophysiological parameters may be related to the small sample size.

There are no studies currently available comparing the effects of continuous and pulsed US. The relatively small number of patients and lack of data describing a long-term follow-up of the patients were the main limitations of our study.

In our study, splinting therapy in combination with pulsed or continuous US or placebo showed similar clinical results. Patients who were treated with continuous and pulsed US showed electrophysiological improvement; however, the results that were obtained, were not superior to those that were reported with the placebo. There is still no existing consensus on optimal therapeutic US parameters and well-designed studies with long-term follow-up are needed.
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###### 

Demographic characteristics of the patients.

                                      Group 1 (n = 15)Mean ± SD   Group 2 (n = 16)Mean ± SD   Group 3 (n = 15)Mean ± SD   *p*-value
  ----------------------------------- --------------------------- --------------------------- --------------------------- -----------
  **Age (years)**                     45.20±2.98                  43.31±2.79                  44.53±2.38                  0.883
  **Duration of symptoms (months)**   13.67±3.52                  12.00±3.29                  11.87±2.70                  0.908

###### 

Comparison of the clinical parameters at baseline and at the end of treatment (post-treatment).

                         Group 1Mean ± SD(n = 15)   Group 2Mean ± SD(n = 16)   Group 3Mean ± SD(n = 15)   *p*-value
  ---------------------- -------------------------- -------------------------- -------------------------- ---------------
  **FSS** **Baseline**   21.33±7.37                 24.00±5.58                 19.00±0.85                 **0**.**019**
  **Post-treatment**     18.80±7.34                 19.31±9.42                 14.20±4.52                 0.125
  ** *p*-value**         **0**.**036**              **0**.**041**              **0**.**003**              
  **SSS** **Baseline**   26.60±8.11                 29.75±7.71                 25.93±4.46                 0.274
  **Post-treatment**     23.06±8.13                 22.06±8.73                 19.66±4.60                 0.442
  ** *p*-value**         **0**.**047**              **0**.**002**              **0**.**001**              
  **VAS** **Baseline**   5.40±2.32                  5.56±1.75                  5.20±1.26                  0.859
  **Post-treatment**     4.40±2.32                  2.68±1.92                  3.53±1.95                  0.083
  ** *p*-value**         **0.006**                  **0.000**                  **0.003**                  

**FSS:** Functional Status Scale.

**SSS:** Symptom Severity Scale.

**VAS:** Visual Analogue Scale.

###### 

Comparison of electrophysiological parameters at baseline and at the end of the treatment (post-treatment).

                                            Group 1Mean ± SD(n = 15)   Group 2Mean ± SD(n = 16)   Group 3Mean ± SD(n = 15)   *p*-value
  ----------------------------------------- -------------------------- -------------------------- -------------------------- -----------
  **Motor NCV** **Baseline**                53.82±4.10                 56.15±4.44                 58.05±6.43                 0.086
  **Post-treatment**                        54.26±4.29                 55.68±5.24                 57.91±5.44                 0.146
  ** *p*-value**                            0.705                      0.766                      0.943                      
  **SDL (digit II to palm)** **Baseline**   3.50±0.72                  3.46±0.68                  3.45±0.58                  0.979
  **Post-treatment**                        3.49±0.96                  3.51±0.61                  3.25±0.69                  0.605
  ** *p*-value**                            0.911                      0.506                      **0.011**                  
  **SDL (palm to wrist) Baseline**          2.76±0.55                  2.75±0.55                  2.79±0.60                  0.318
  **Post-treatment**                        2.76±0.72                  2.65±0.62                  2.84±0.57                  0.912
  ** *p*-value**                            1.00                       **0.042**                  0.336                      
  **Distal motor latency** **Baseline**     4.17±0.70                  4.20±0.90                  4.60±1.23                  0.403
  **Post-treatment**                        4.19±0.82                  4.17±0.086                 4.45±1.37                  0.714
  *** p*-value**                            0.889                      0.725                      0.271                      
  **SNCV(digit II to palm)** **Baseline**   32.74±5.29                 33.13±4.79                 32.26±7.51                 0.922
  **Post-treatment**                        33.76±6.75                 32.53±4.61                 33.32±7.74                 0.866
  ** *p*-value**                            0.214                      0.479                      0.101                      
  **SNCV (palm to wrist) Baseline**         25.46±6.75                 26.28±4.17                 27.04±5.65                 0.743
  **Post treatment**                        26.82±6.25                 29.66±6.09                 32.03±6.84                 0.094
  ** *p*-value**                            0.203                      **0.008**                  **0.003**                  

**SNCV:** Sensory nerve conduction velocity.

**SDL:** Sensory distal latency.

[^1]: Armagan O was the study director. Bakilan F, Ozgen M and Mehmetoglu O were the assistant directors. Oner S was the co-assistant for the statistical analyses.
